Resumo Antecedentes Indivíduos com ataxia espinocerebelar tipo 3 (AEC3) apresentam distúrbios da comunicação e deterioração da deglutição e, consequentemente, na qualidade de vida (QV). Objetivo Avaliar o impacto de um programa de reabilitação fonoaudiológica na QV em pacientes com AEC3. Métodos Todos os participantes foram alocados aleatoriamente em dois grupos, um grupo intervenção que recebeu terapia fonoaudiológica (GTF) e um grupo controle (GC). As pontuações das escalas: International Cooperative Ataxia Rating Scale (ICARS) foram 32,4 ± 20,2 e da Scale for the Assessment and Rating of Ataxia (SARA) foram 11,8 ± 8,0. A intervenção consistiu em um programa de reabilitação fonoaudiológica de 12 sessões composto por exercícios de fortalecimento oral, faríngeo e laríngeo - denominados ATAXIA - Terapia Miofuncional Orofacial e Vocal (A-TMOV). Todos foram submetidos a avaliações pré e pós-intervenção por meio dos protocolos World Health Organization's Quality of Life (WHOQOL-BREF), Vivendo com Disartria (VcD), Quality of Life in Swallowing Disorders (SWAL-QOL) e Food Assessment Tool (EAT-10). Resultados A amostra foi composta por 48 pacientes com AEC3 (25 no GTF e 23 no GC), média de idade 47,1 ± 11,4anos; média de idade de início dos sintomas 36,9 ± 11,3anos; duração da doença 11,9 ± 13,3anos. Após intervenção de três meses, houve mudanças significativas na QV no GTF em comparação com o GC quando avaliado pelo VcD (179,12 ± 62,55 versus129,88 ± 51,42, p < 0,001), SWAL-QOL (869,43 ± 153,63 versus 911,60 ± 130,90, p = 0,010), EAT-10 (5,16 ± 7,55 versus 2,08 ± 3,85, p = 0,018). Conclusões Pacientes com AEC3 devem receber terapia fonoaudiológica contínua como parte do programa A-TMOV, pois a terapia ajuda a melhorar a dificuldade de deglutição e a disartria. AEC (AEC3 consequentemente QV. . (QV) grupos (GTF GC. (GC) escalas ICARS (ICARS 324 32 4 32, 202 20 2 20, SARA (SARA 118 11 8 11, 80 0 8,0 1 oral ATMOV. ATMOV TMOV (A-TMOV) pósintervenção pós Organizations Organization s WHOQOLBREF, WHOQOLBREF WHOQOL BREF , (WHOQOL-BREF) VcD, (VcD) SWALQOL SWAL QOL (SWAL-QOL EAT10. EAT10 EAT 10 (EAT-10) 25 (2 GC, GC) 471 47 47, 11,4anos 114anos anos 4anos 369 36 9 36, 11,3anos 113anos 3anos 119 133anos 13 13,3anos meses 179,12 17912 179 (179,1 6255 62 55 62,5 versus12988 versus129 88 versus129,8 5142 51 42 51,42 0,001, 0001 0,001 001 0,001) 869,43 86943 869 43 (869,4 15363 153 63 153,6 91160 911 60 911,6 13090 130 90 130,90 0,010, 0010 0,010 010 0,010) EAT-1 5,16 516 5 16 (5,1 755 7 7,5 208 08 2,0 385 85 3,85 0,018. 0018 0,018 018 0,018) ATMOV, TMOV, A-TMOV disartria (AEC (QV (GC 8, (A-TMOV (WHOQOL-BREF (VcD EAT1 (EAT-10 ( 179,1 1791 17 (179, 625 6 62, versus1298 versus12 versus129, 514 51,4 000 0,00 00 869,4 8694 86 (869, 1536 15 153, 9116 91 911, 1309 130,9 0,01 01 EAT- 5,1 (5, 75 7, 2, 38 3,8 (EAT-1 179, (179 versus1 51, 0,0 869, (869 130, 5, (5 3, (EAT- (17 0, (86 (EAT (1 (8
Abstract Background Individuals with spinocerebellar ataxia type 3 (SCA3) present communication and swallowing disorders, and consequent deterioration in quality of life (QOL). Objective To evaluate the impact of a speech therapy rehabilitation program on the QOL of patients with SCA3. Methods All participants were randomly assigned to two groups, an intervention group receiving speech therapy (STG) and a control group (CG). The International Cooperative Ataxia Rating Scale scores were 32.4 ± 20.2, and the Scale for the Assessment and Rating of Ataxia scores were 11.8 ± 8.0. The intervention consisted of a 12-session speech therapy rehabilitation program with oral, pharyngeal, and laryngeal strengthening exercises—the so-called ATAXIA–Myofunctional Orofacial and Vocal Therapy (A-MOVT). They all were submitted to pre- and postintervention evaluations using the World Health Organization's Quality of Life (WHOQOL-BREF) assessment, as well as the Living with Dysarthria (LwD), Quality of Life in Swallowing Disorders (SWAL-QOL), and Food Assessment Tool (EAT-10). Results The study sample consisted of 48 patients with SCA3 (STG = 25; CG = 23), mean age was 47.1 ± 11.4 years; mean age at symptom onset was 36.9 ± 11.3 years; disease duration was 11.9 ± 13.3 years. After the 3-month intervention, there were significant changes in the QOL in the STG compared with the CG, when assessed by the LwD (179.12 ± 62.55 vs. 129.88 ± 51.42, p < 0.001), SWAL-QOL (869.43 ± 153.63 vs. 911.60 ± 130.90, p = 0.010), and EAT-10 (5.16 ± 7.55 vs. 2.08 ± 3.85, p = 0.018). Conclusions Patients with SCA3 should receive continuous speech therapy as part of the A-MOVT program, because therapy helps to improve difficulty swallowing and dysarthria. SCA (SCA3 disorders QOL. . (QOL) groups CG. (CG) 324 32 4 32. 202 20 2 20.2 118 11 8 11. 80 0 8.0 12session session 12 oral pharyngeal exercisesthe exercises socalled so called ATAXIAMyofunctional ATAXIA Myofunctional AMOVT. AMOVT A MOVT (A-MOVT) pre Organizations Organization s WHOQOLBREF WHOQOL BREF (WHOQOL-BREF assessment LwD, , (LwD) SWALQOL, SWALQOL SWAL (SWAL-QOL) EAT10. EAT10 EAT 10 (EAT-10) 25 23, 23 23) 471 47 1 47. 114 years 369 36 9 36. 113 119 133 13 13. 3month month 179.12 17912 179 (179.1 6255 62 55 62.5 vs 12988 129 88 129.8 5142 51 42 51.42 0.001, 0001 0.001 001 0.001) 869.43 86943 869 43 (869.4 15363 153 63 153.6 91160 911 60 911.6 13090 130 90 130.90 0.010, 0010 0.010 010 0.010) EAT-1 5.16 516 5 16 (5.1 755 7 7.5 208 08 2.0 385 85 3.85 0.018. 0018 0.018 018 0.018) dysarthria (SCA (QOL (CG 20. 8. (A-MOVT (LwD (SWAL-QOL EAT1 (EAT-10 179.1 1791 17 (179. 625 6 62. 1298 129. 514 51.4 000 0.00 00 869.4 8694 86 (869. 1536 15 153. 9116 91 911. 1309 130.9 0.01 01 EAT- 5.1 (5. 75 7. 2. 38 3.8 (EAT-1 179. (179 51. 0.0 869. (869 130. 5. (5 3. (EAT- (17 0. (86 ( (EAT (1 (8